Mangoceuticals Advances Antiviral Research on its Patented Respiratory Illness Prevention Technology

Mangoceuticals, Inc. recenntly announced it is advancing its research into respiratory illness prevention technologies by focusing on finding a practical, everyday solution to combat avian influenza viruses (H5N1), specifically within the poultry industry.

The company has engaged Vipragen Biosciences, an AAALAC-accredited preclinical Contract Research Organization (CRO) based in Mysuru, India (Vipragen), to conduct independent efficacy studies aimed at developing an antiviral solution for respiratory illnesses in humans. These studies are based on the Company’s acquisition of patented respiratory illness prevention technology from IntraMont Technologies, Inc. (IntraMont). Phase 1 animal studies have already demonstrated significant efficacy in reducing lung viral load, and the compounds are now advancing into Phase 2 animal studies.

Mangoceuticals is leveraging this same technology to assess the feasibility of a drinking water-based application for poultry. The study is planned to focus on testing the efficacy of this solution when administered through drinking water and evaluating any necessary modifications to optimize its effectiveness in preventing avian flu infections among poultry populations.

Unlike traditional approaches that rely on synthetic vaccines or pharmaceutical treatments, Mangoceuticals’ antiviral technology leverages Generally Recognized as Safe (GRAS) ingredients added to poultry drinking water. This method, we believe, may offer a simple, compliant, and non-pharmaceutical way to strengthen immune defenses in poultry. Following the Phase 1 animal studies, which concluded in late December, and pending promising results from the ongoing Phase 2 studies, though no assurances can be made, the company believes this solution has the potential to be an effective tool in reducing the spread of H5N1 avian flu.

The ongoing avian flu outbreak has inflicted catastrophic losses on the poultry industry, leading to the culling of more than 148 million birds in the US alone since 2022. These aggressive containment measures have crippled egg and poultry production, disrupted global supply chains, and sent consumer prices soaring. As of December 2024, the national average price of eggs hit $4.15 per dozen, with forecasts predicting an additional 20% increase in 2025.

In addition to direct losses from outbreaks, farms are extending significant amounts of resources on biosecurity measures and disease prevention strategies to protect flocks. Despite these costly efforts, avian flu remains a persistent threat, requiring a more effective and cost-efficient approach. Mangoceuticals’ water-based antiviral technology aims to significantly reduce these expenses by hopefully providing a proactive, scalable, and easily deployable solution to help prevent infections before they spread.

“The rise in global avian flu outbreaks is not just an agricultural issue, it’s a potential global health crisis,” said Jacob Cohen, Founder and CEO of Mangoceuticals, who continued, “Our initial animal study research has indicated and already demonstrated significant efficacy in reducing viral loads in respiratory illnesses, and now we’re taking the next step to evaluate how this same technology may be applied through poultry drinking water as a preventive measure. We believe that if proven effective in studies, this could be a simple, everyday solution that fits seamlessly into existing poultry farming practices while reducing the financial strain on farmers.”

With the global poultry market projected to reach $375.41 billion by 2030, we believe that Mangoceuticals’ water-based antiviral solution could, if proven successful in further studies, revolutionize disease prevention in livestock and provide poultry farmers with a powerful new tool against avian flu while helping to lower industry-wide costs.

As outbreaks continue to rise, Mangoceuticals remains committed to delivering effective, simple, and scalable solutions that protect livestock, stabilize the food supply, and prevent future pandemics. The Company anticipates sharing final study results upon completion of the study, while ensuring proper intellectual property protections ahead of commercialization.

MangoRx is focused on developing a variety of men’s health and wellness products and services via a secure telemedicine platform. To date, the company has identified men’s wellness telemedicine services and products as a growing sector and especially related to the area of erectile dysfunction (ED), hair growth, hormone replacement therapies, and weight management. Interested consumers can use MangoRx’s telemedicine platform for a smooth experience. Prescription requests will be reviewed by a physician and, if approved, fulfilled and discreetly shipped through MangoRx’s partner compounding pharmacy and right to the patient’s doorstep. To learn more about MangoRx’s mission and other products, please visit www.MangoRx.com.